Serum 25-Hydroxyvitamin D and Cancer Risk: A Systematic Review of Mendelian Randomization Studies
Nutrients · 2023
DOI: 10.3390/nu15020422 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Nutrients, 2023. Verfasst von Thomas Lawler und 1 weiteren Autor:innen. Beteiligte Einrichtung: Carbone Cancer Center, University of Wisconsin-Madison, Madison, WI 53726, USA. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Lung Neoplasms, Colorectal Neoplasms. Die Arbeit wurde bisher 55-mal zitiert (Crossref) und nennt 91 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council, NCI NIH HHS, National Cancer Institute of the National Institutes of Health [NIH/NCI].
Abstract (Originalsprache)
Epidemiological studies suggest that higher serum 25-hydroxyvitamin D is associated with lower risk for several cancers, including breast, prostate, colorectal, and lung cancers. To mitigate confounding, genetic instrumental variables (IVs) have been used to estimate causal associations between 25-hydroxivtamin D and cancer risk via Mendelian randomization (MR). We provide a systematic review of 31 MR studies concerning 25-hydroxyvitamin D and cancer incidence and mortality identified from biomedical databases. MR analyses were conducted almost exclusively in European-ancestry populations and identified no statistically significant associations between higher genetically predicted 25-hydroxyvitamin D and lower risk for total cancer or colorectal, breast, prostate, lung, or pancreatic cancers. In recent studies including ≥80 genetic IVs for 25-hydroxyvitamin D, null associations were reported for total cancer (odds ratio [95% confidence interval] per 1-standard deviation increase: 0.98 [0.93–1.04]), breast (1.00 [0.98–1.02]), colorectal (0.97 [0.88–1.07]), prostate (0.99 [0.98–1.01]), and lung cancer (1.00 [0.93–1.03]). A protective association was observed for ovarian cancer in the Ovarian Cancer Association Consortium (0.78 [0.63–0.96] per 20 nmol/L increase, p-trend = 0.03), but not in the UK Biobank (1.10 [0.80–1.51]). Null associations were reported for other tumor sites (bladder, endometrium, uterus, esophagus, oral cavity and pharynx, kidney, liver, thyroid, or neural cells). An inconsistent protective association for cancer-specific mortality was also observed. Results from MR analyses do not support causal associations between 25-hydroxyvitamin D and risk for cancer incidence or mortality. Studies including non-White populations may be valuable to understand low 25-hydroxyvitamin D as a modifiable risk factor in populations with a higher risk of common cancers, including African ancestry individuals.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Carbone Cancer Center, University of Wisconsin-Madison, Madison, WI 53726, USA.
- Department of Population Health Sciences, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI 53726, USA.
ORCID-Profile: Thomas Lawler
Förderung
- Medical Research Council
- NCI NIH HHS
- National Cancer Institute of the National Institutes of Health [NIH/NCI]
Zitieren
APA
Lawler, T., & Warren Andersen, S. (2023). Serum 25-Hydroxyvitamin D and Cancer Risk: A Systematic Review of Mendelian Randomization Studies. Nutrients. https://doi.org/10.3390/nu15020422
Vancouver
Lawler T, Warren Andersen S. Serum 25-Hydroxyvitamin D and Cancer Risk: A Systematic Review of Mendelian Randomization Studies. Nutrients. 2023. doi:10.3390/nu15020422
BibTeX
@article{Lawler2023,
author = {Lawler, Thomas and Warren Andersen, Shaneda},
title = {Serum 25-Hydroxyvitamin D and Cancer Risk: A Systematic Review of Mendelian Randomization Studies},
journal = {Nutrients},
year = {2023},
doi = {10.3390/nu15020422}
}
EUVIMED